搜索
Search
这是描述信息

About Livzon

/
Milestones

2021

The Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed in collaboration by Institute of Biophysics in the Chinese Academy of Sciences and Livzon Mabpharm Inc., a subsidiary of Livzon Pharmaceutical Group, has obtained the clinical approval from the National Medical Products Administration, and is currently conducting multi-reginal Phase III clinical trials.
04month 2022

2020

Corporate culture reform with mission of "Patient Quality of Life Comes First" and vision of "Be the Pharmaceutical Industry Leader"
11month 2021

2016

Livzon new industrial park completed
11month 2021

2014

B-share stock transfer to H-share stock
11month 2021

2010

Focused on the field of biological products, and established monoclonal antibody company
11month 2021

2008

Foundations laid for Livzon new industrial park, which is a domestic leading, world-class modern pharmaceutical production base
11month 2021

2002

Completed shareholding system reform, and became the first listed company both in A-share and B-share stock markets in domestic pharmaceutical industry
11month 2021

1993

Completed shareholding system reform, and became the first listed company both in A-share and B-share stock markets in domestic pharmaceutical industry
11month 2021

1989

Livzon Dele marketed, and the brand status established
11month 2021

1985

Founded in January 1985
11month 2021

Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China    Tel: 0756-8135888    

©2021 Livzon  粤ICP备05025993-4号  Support:300.cn

Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China  

©2021 Livzon   粤ICP备05025993号  

 Support:300.cn